News and Trends 10 Sep 2015
Roche adds AveXis to its SMA portfolio – determined to dominate market
Swiss Roche is looking to dominate market in Spinal Muscular Atrophy (SMA) research, now also investing in AveXis as part of €58M series D investment in their SMA one-time treatment…